SG130192A1 - Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators - Google Patents

Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Info

Publication number: SG130192A1
Authority: SG; Singapore
Prior art keywords: group; benzthiazole; benzimidazole; lta4h; benzoxazole derivatives
Prior art date: 2003-07-28

Application number

SG200700817-0A

Other languages

English (en)

Inventor

Frank U Axe

Scott D Bembenek

Christopher R Butler

James P Edwards

Anne M Fourie

Cheryl A Grice

Brad M Savall

Kevin L Tays

Jianmei Wei

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-28

Filing date

2004-07-27

Publication date

2007-03-20

2004-07-27 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2007-03-20 Publication of SG130192A1 publication Critical patent/SG130192A1/en

Links

IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title 2
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical class C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 title 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
108010072713 leukotriene A4 hydrolase Proteins 0.000 abstract 3
206010061218 Inflammation Diseases 0.000 abstract 2
102100022118 Leukotriene A-4 hydrolase Human genes 0.000 abstract 2
230000004054 inflammatory process Effects 0.000 abstract 2
230000005764 inhibitory process Effects 0.000 abstract 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Manufacturing & Machinery (AREA)
Ceramic Engineering (AREA)
Materials Engineering (AREA)
Biomedical Technology (AREA)
Structural Engineering (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SG200700817-0A 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators SG130192A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US49071003P	2003-07-28	2003-07-28

Publications (1)

Publication Number	Publication Date
SG130192A1 true SG130192A1 (en)	2007-03-20

Family

ID=34115427

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG200700817-0A SG130192A1 (en)	2003-07-28	2004-07-27	Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
SG200700691A SG129449A1 (en)	2003-07-28	2004-07-27	Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG200700691A SG129449A1 (en)	2003-07-28	2004-07-27	Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators

Country Status (28)

Country	Link
US (2)	US20050043379A1 (de)
EP (2)	EP1660491B1 (de)
JP (2)	JP4726238B2 (de)
KR (2)	KR20060054408A (de)
CN (2)	CN100591679C (de)
AR (2)	AR045730A1 (de)
AT (2)	ATE405562T1 (de)
AU (2)	AU2004261628B2 (de)
BR (2)	BRPI0413072A (de)
CA (2)	CA2534228A1 (de)
CY (1)	CY1108560T1 (de)
DE (2)	DE602004016002D1 (de)
DK (2)	DK1660492T3 (de)
ES (2)	ES2313079T3 (de)
HR (2)	HRP20060041B1 (de)
IL (1)	IL173372A (de)
MY (1)	MY145080A (de)
NO (2)	NO20060771L (de)
NZ (2)	NZ544970A (de)
PL (2)	PL1660491T3 (de)
PT (2)	PT1660491E (de)
RU (2)	RU2373204C2 (de)
SG (2)	SG130192A1 (de)
SI (2)	SI1660491T1 (de)
TW (2)	TW200520756A (de)
UA (2)	UA87986C2 (de)
WO (2)	WO2005012297A1 (de)
ZA (2)	ZA200601716B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1660491E (pt) *	2003-07-28	2008-10-10	Janssen Pharmaceutica Nv	Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h
EP1868605A2 (de) *	2005-03-31	2007-12-26	Janssen Pharmaceutica, N.V.	Phenyl- und pyridyl-lta4h-modulatoren
US20080306054A1 (en)	2005-04-13	2008-12-11	Astex Therapeutics Limited	Pharmaceutical Compounds
EP1717235A3 (de) *	2005-04-29	2007-02-28	Bioprojet	Phenoxypropylpiperidine und -pyrrolidine und ihre Verwendung als Liganden für den Histamin H3-Rezeptor
KR101047221B1 (ko) *	2005-09-02	2011-07-06	에프. 호프만-라 로슈 아게	벤조옥사졸, 옥사졸로피리딘, 벤조싸이아졸 및싸이아졸로피리딘 유도체
EA017618B1 (ru) *	2005-09-21	2013-01-30	Декод Дженетикс Ехф	Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
CA2634701C (en)	2005-12-21	2014-07-29	Decode Genetics Ehf	Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
EP1963276B9 (de) *	2005-12-21	2012-09-26	Decode Genetics EHF	N-gebundene arylheteroarylinhibitoren von lta4h zur behandlung von enzündungen
CA2636929A1 (en) *	2005-12-21	2007-07-12	Decode Genetics, Ehf	Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
EP1976828B1 (de) *	2005-12-29	2016-12-21	Celtaxsys, Inc.	Diaminderivate als inhibitoren von leukotrien-a4-hydrolase
EP1987009A1 (de) *	2006-01-30	2008-11-05	Euro-Celtique S.A.	Cycloharnstoffverbindung als calciumkanalblocker
US7754725B2 (en)	2006-03-01	2010-07-13	Astex Therapeutics Ltd.	Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) *	2006-05-03	2011-05-31	Janssen Pharmaceutica Nv	Benzimidazole modulators of VR1
JP5318757B2 (ja) *	2006-06-16	2013-10-16	ハー・ルンドベック・アクチエゼルスカベット	神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形
WO2008019284A1 (en) *	2006-08-04	2008-02-14	Decode Genetics Ehf	Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
US8115005B2 (en)	2006-08-04	2012-02-14	Decode Genetics Ehf.	Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
WO2008019306A2 (en) *	2006-08-04	2008-02-14	Decode Genetics Ehf	Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
WO2008044045A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
GB0620259D0 (en)	2006-10-12	2006-11-22	Astex Therapeutics Ltd	Pharmaceutical compounds
JP5721949B2 (ja)	2006-10-12	2015-05-20	アステックス、セラピューティックス、リミテッドＡｓｔｅｘＴｈｅｒａｐｅｕｔｉｃｓＬｉｍｉｔｅｄ	複合薬剤
WO2008044041A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
JP5518478B2 (ja)	2006-10-12	2014-06-11	アステックス、セラピューティックス、リミテッド	医薬化合物
CL2008000468A1 (es) *	2007-02-14	2008-08-22	Janssen Pharmaceutica Nv	Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
WO2008109702A1 (en) *	2007-03-08	2008-09-12	Irm Llc	Compounds and compositions as modulators of gpr119 activity
JPWO2008120710A1 (ja) *	2007-03-30	2010-07-15	パナソニック電工株式会社	活動強度計
PA8802501A1 (es) *	2007-10-31	2009-06-23	Janssen Pharmaceutica Nv	Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa
RU2472509C2 (ru) *	2007-11-16	2013-01-20	Эбботт Лэборетриз	Способ лечения артрита
GB0806527D0 (en)	2008-04-11	2008-05-14	Astex Therapeutics Ltd	Pharmaceutical compounds
CA2721099C (en) *	2008-04-11	2017-04-25	Janssen Pharmaceutica Nv	Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
US8759345B2 (en)	2008-04-28	2014-06-24	Janssen Pharmaceutica Nv	Benzoimidazoles as prolyl hydroxylase inhibitors
NZ596137A (en) *	2009-05-14	2013-08-30	Janssen Pharmaceutica Nv	Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
CN102442962A (zh) *	2010-11-10	2012-05-09	江苏德峰药业有限公司	1-烷基四氮唑的生产方法
CN102442961A (zh) *	2010-11-10	2012-05-09	江苏德峰药业有限公司	1-甲基四氮唑的生产方法
ES2818977T3 (es)	2011-10-25	2021-04-14	Janssen Pharmaceutica Nv	Método para obtener cristales de sal de meglumina de ácido 1-(5,6-dicloro-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico
ES2864862T3 (es)	2013-03-12	2021-10-14	Celltaxis Llc	Métodos de inhibición de la leucotrieno A4 hidrolasa
MX2015011678A (es)	2013-03-14	2016-07-08	Celtaxsys Inc	Inhibidores de leucotrieno a4 hidrolasa.
CA2906086A1 (en)	2013-03-14	2014-09-25	Celtaxsys, Inc.	Inhibitors of leukotriene a4 hydrolase
MX2015011677A (es)	2013-03-14	2016-07-08	Celtaxsys Inc	Inhibidores de leucotrieno a4 hidrolasa.
CN105793242B (zh) *	2013-12-17	2018-02-16	伊莱利利公司	苯氧基乙基环状胺衍生物及其作为ep4受体调节剂的活性
US10752588B2 (en)	2014-12-19	2020-08-25	The Broad Institute, Inc.	Dopamine D2 receptor ligands
EP3233077B1 (de)	2014-12-19	2026-05-06	The Broad Institute, Inc.	Dopamin-d2-rezeptor-liganden
HUE047988T2 (hu)	2015-06-09	2020-05-28	Abbvie Inc	Nukleáris receptor modulátorok (ROR) gyulladásos és autoimmun betegségek kezelésére
MX2019007411A (es)	2016-12-21	2019-08-29	Hoffmann La Roche	Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
EP3559249A1 (de)	2016-12-21	2019-10-30	H. Hoffnabb-La Roche Ag	Verfahren zum in-vitro-glycoengineering von antikörpern
CN107663192B (zh) *	2017-11-03	2019-05-10	梯尔希（南京）药物研发有限公司	一种雷贝拉唑杂质的制备方法
US10898484B2 (en)	2018-05-31	2021-01-26	Celltaxis, Llc	Method of reducing pulmonary exacerbations in respiratory disease patients
EP3870292A4 (de)	2018-10-26	2022-11-09	The Research Foundation for The State University of New York	Kombination von serotonin-spezifischem wiederaufnahmeinhibitor und serotonin-1a-rezeptor-partialagonist zur verminderung von l-dopa-induzierter dyskinesie
CN113784713A (zh) *	2019-01-11	2021-12-10	纳吉斯制药股份有限公司	白三烯合成抑制剂
CN110026557B (zh) *	2019-05-28	2021-08-27	南方科技大学	一种混合固体颗粒重熔的直写装置及成型方法
EP4247374A4 (de) *	2020-11-19	2024-10-09	Telo Therapeutics, Inc.	Kleinmolekülige verbindungen und zusammensetzungen
US11932630B2 (en) *	2021-04-16	2024-03-19	Novartis Ag	Heteroaryl aminopropanol derivatives
CN113683491A (zh) *	2021-09-01	2021-11-23	王传良	一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) *	2021-09-27	2022-07-12	安徽美致诚药业有限公司	一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4873346A (en)	1985-09-20	1989-10-10	The Upjohn Company	Substituted benzothiazoles, benzimidazoles, and benzoxazoles
CA1319144C (en) *	1986-11-14	1993-06-15	Quirico Branca	Tetrahydronaphthalene derivatives
IL90337A0 (en) *	1988-05-24	1989-12-15	Pfizer	Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
IT1240598B (it) *	1990-03-13	1993-12-17	Mini Ricerca Scient Tecnolog	Derivati amminici ad azione antifungina
US5585492A (en) *	1994-10-11	1996-12-17	G. D. Searle & Co.	LTA4 Hydrolase inhibitors
IL117149A0 (en) *	1995-02-23	1996-06-18	Schering Corp	Muscarinic antagonists
US5889006A (en) *	1995-02-23	1999-03-30	Schering Corporation	Muscarinic antagonists
US5925654A (en) *	1997-03-12	1999-07-20	G.D. Searle & Co.	LTA4 , hydrolase inhibitors
CA2322163A1 (en) *	1998-02-25	1999-09-02	John Mckew	Inhibitors of phospholipase a2
US6514964B1 (en) *	1999-09-27	2003-02-04	Amgen Inc.	Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) *	2002-03-21	2004-06-10	Thomas Arrhenius	Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
PT1660491E (pt) *	2003-07-28	2008-10-10	Janssen Pharmaceutica Nv	Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h
US7541466B2 (en) *	2003-12-23	2009-06-02	Genzyme Corporation	Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
MX2007011273A (es) *	2005-03-16	2007-11-08	Meda Pharma Gmbh & Co Kg	La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
CL2008000468A1 (es) *	2007-02-14	2008-08-22	Janssen Pharmaceutica Nv	Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.

2004
- 2004-07-27 PT PT04779219T patent/PT1660491E/pt unknown
- 2004-07-27 SI SI200430904T patent/SI1660491T1/sl unknown
- 2004-07-27 RU RU2006102510/04A patent/RU2373204C2/ru not_active IP Right Cessation
- 2004-07-27 DK DK04779375T patent/DK1660492T3/da active
- 2004-07-27 KR KR1020067002211A patent/KR20060054408A/ko not_active Ceased
- 2004-07-27 AT AT04779375T patent/ATE405562T1/de active
- 2004-07-27 AU AU2004261628A patent/AU2004261628B2/en not_active Ceased
- 2004-07-27 EP EP04779219A patent/EP1660491B1/de not_active Expired - Lifetime
- 2004-07-27 HR HRP20060041AA patent/HRP20060041B1/hr not_active IP Right Cessation
- 2004-07-27 BR BRPI0413072-3A patent/BRPI0413072A/pt not_active IP Right Cessation
- 2004-07-27 UA UAA200601433A patent/UA87986C2/uk unknown
- 2004-07-27 AU AU2004261610A patent/AU2004261610B2/en not_active Ceased
- 2004-07-27 NZ NZ544970A patent/NZ544970A/en unknown
- 2004-07-27 EP EP04779375A patent/EP1660492B1/de not_active Expired - Lifetime
- 2004-07-27 NZ NZ544938A patent/NZ544938A/en unknown
- 2004-07-27 CA CA002534228A patent/CA2534228A1/en not_active Abandoned
- 2004-07-27 WO PCT/US2004/024309 patent/WO2005012297A1/en not_active Ceased
- 2004-07-27 SI SI200430927T patent/SI1660492T1/sl unknown
- 2004-07-27 KR KR1020067002194A patent/KR101149379B1/ko not_active Expired - Fee Related
- 2004-07-27 UA UAA200601432A patent/UA82888C2/uk unknown
- 2004-07-27 JP JP2006522022A patent/JP4726238B2/ja not_active Expired - Fee Related
- 2004-07-27 CN CN200480028138A patent/CN100591679C/zh not_active Expired - Fee Related
- 2004-07-27 ES ES04779375T patent/ES2313079T3/es not_active Expired - Lifetime
- 2004-07-27 HR HR20060039A patent/HRP20060039A2/xx not_active Application Discontinuation
- 2004-07-27 PL PL04779219T patent/PL1660491T3/pl unknown
- 2004-07-27 PL PL04779375T patent/PL1660492T3/pl unknown
- 2004-07-27 DE DE602004016002T patent/DE602004016002D1/de not_active Expired - Lifetime
- 2004-07-27 US US10/900,152 patent/US20050043379A1/en not_active Abandoned
- 2004-07-27 US US10/900,103 patent/US20050043378A1/en not_active Abandoned
- 2004-07-27 PT PT04779375T patent/PT1660492E/pt unknown
- 2004-07-27 DK DK04779219T patent/DK1660491T3/da active
- 2004-07-27 AT AT04779219T patent/ATE403654T1/de not_active IP Right Cessation
- 2004-07-27 DE DE602004015620T patent/DE602004015620D1/de not_active Expired - Lifetime
- 2004-07-27 SG SG200700817-0A patent/SG130192A1/en unknown
- 2004-07-27 WO PCT/US2004/024050 patent/WO2005012296A1/en not_active Ceased
- 2004-07-27 CN CNA2004800279067A patent/CN1856490A/zh active Pending
- 2004-07-27 ES ES04779219T patent/ES2311858T3/es not_active Expired - Lifetime
- 2004-07-27 CA CA002534212A patent/CA2534212A1/en not_active Abandoned
- 2004-07-27 BR BRPI0412345-0A patent/BRPI0412345A/pt not_active IP Right Cessation
- 2004-07-27 JP JP2006521973A patent/JP2007500703A/ja active Pending
- 2004-07-27 SG SG200700691A patent/SG129449A1/en unknown
- 2004-07-27 RU RU2006102508/04A patent/RU2359970C2/ru not_active IP Right Cessation
- 2004-07-28 AR ARP040102683A patent/AR045730A1/es not_active Application Discontinuation
- 2004-07-28 MY MYPI20043045A patent/MY145080A/en unknown
- 2004-07-28 TW TW093122566A patent/TW200520756A/zh unknown
- 2004-07-28 TW TW093122570A patent/TWI362383B/zh not_active IP Right Cessation
- 2004-07-28 AR ARP040102682A patent/AR045729A1/es unknown
2006
- 2006-01-26 IL IL173372A patent/IL173372A/en not_active IP Right Cessation
- 2006-02-17 NO NO20060771A patent/NO20060771L/no not_active Application Discontinuation
- 2006-02-20 NO NO20060823A patent/NO20060823L/no not_active Application Discontinuation
- 2006-02-27 ZA ZA200601716A patent/ZA200601716B/en unknown
- 2006-02-27 ZA ZA200601720A patent/ZA200601720B/en unknown
2008
- 2008-10-27 CY CY20081101220T patent/CY1108560T1/el unknown

Also Published As

Publication number	Publication date
RU2359970C2 (ru)	2009-06-27
HK1092790A1 (en)	2007-02-16
DE602004016002D1 (de)	2008-10-02
IL173372A (en)	2010-11-30
JP2007500703A (ja)	2007-01-18
HK1090359A1 (en)	2006-12-22
NO20060771L (no)	2006-04-21
SG129449A1 (en)	2007-02-26
RU2006102510A (ru)	2006-07-27
EP1660492A1 (de)	2006-05-31
KR101149379B1 (ko)	2012-06-28
DE602004015620D1 (de)	2008-09-18
EP1660491B1 (de)	2008-08-06
CA2534228A1 (en)	2005-02-10
MY145080A (en)	2011-12-15
KR20060054408A (ko)	2006-05-22
ATE405562T1 (de)	2008-09-15
TWI362383B (en)	2012-04-21
DK1660492T3 (da)	2008-11-03
KR20060057593A (ko)	2006-05-26
BRPI0412345A (pt)	2006-10-03
RU2373204C2 (ru)	2009-11-20
DK1660491T3 (da)	2008-11-10
ATE403654T1 (de)	2008-08-15
CN1860117A (zh)	2006-11-08
CY1108560T1 (el)	2014-04-09
WO2005012296A1 (en)	2005-02-10
US20050043379A1 (en)	2005-02-24
JP4726238B2 (ja)	2011-07-20
SI1660492T1 (sl)	2009-02-28
ZA200601720B (en)	2007-11-28
AU2004261610A1 (en)	2005-02-10
PL1660491T3 (pl)	2009-01-30
HRP20060039A2 (en)	2006-08-31
SI1660491T1 (sl)	2009-02-28
US20050043378A1 (en)	2005-02-24
WO2005012297A9 (en)	2007-01-04
CN100591679C (zh)	2010-02-24
NO20060823L (no)	2006-03-15
PL1660492T3 (pl)	2009-01-30
TW200523255A (en)	2005-07-16
NZ544970A (en)	2009-02-28
ES2311858T3 (es)	2009-02-16
AR045730A1 (es)	2005-11-09
BRPI0413072A (pt)	2006-10-03
JP2007500706A (ja)	2007-01-18
UA82888C2 (en)	2008-05-26
WO2005012297A1 (en)	2005-02-10
HRP20060041A2 (en)	2006-11-30
TW200520756A (en)	2005-07-01
CN1856490A (zh)	2006-11-01
AU2004261628B2 (en)	2011-05-12
EP1660491A1 (de)	2006-05-31
HRP20060041B1 (hr)	2014-06-06
AU2004261628A1 (en)	2005-02-10
AR045729A1 (es)	2005-11-09
CA2534212A1 (en)	2005-02-10
ES2313079T3 (es)	2009-03-01
EP1660492B1 (de)	2008-08-20
ZA200601716B (en)	2007-05-30
PT1660491E (pt)	2008-10-10
RU2006102508A (ru)	2006-07-27
NZ544938A (en)	2009-05-31
IL173372A0 (en)	2006-06-11
UA87986C2 (uk)	2009-09-10
PT1660492E (pt)	2008-11-13
AU2004261610B2 (en)	2010-05-20

Publication	Publication Date	Title
UA87986C2 (uk)	2009-09-10	Бензімідазольні, бензтіазольні та бензоксазольні похідні і їх застосування як lta4h модуляторів
FI970150A0 (fi)	1997-01-14	Substituoituja pyrimidiiniyhdisteitä ja niiden käyttö
SI1070056T1 (en)	2004-12-31	Phthalazinone pde iii/iv inhibitors
PT771197E (pt)	2003-08-29	Utilizacao de compostos heterociclicos como ligantes de dopamina-d 3
NZ539841A (en)	2007-11-30	Hydroxyethylamine derivatives for the treatment of alzheimer's disease
FI970246A7 (fi)	1997-01-21	Dihydrobentsofuraanit
BG105561A (en)	2001-12-29	Phenylphenanthridines with pde-iv inhibiting activity
PT1000035E (pt)	2003-04-30	6-fenilfenantridinas substituidas
BG108674A (bg)	2005-04-30	Пиперазинови производни с ccr1 рецепторна антагонистична активност
YU19499A (sh)	2001-09-28	Benzonaftiridini kao bronhijalni terapeutici
YU401A (sh)	2003-10-31	Sredstva sa antidepresivnim dejstvom
FI970149A0 (fi)	1997-01-14	Tiatsoli- ja tiadiatsoliyhdisteiden käyttö D3-reseptoriligandeina
DE60022227D1 (de)	2005-09-29	2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung
MY128323A (en)	2007-01-31	Thiazole derivatives for inhibition of cytokine production and of cell adhesion
DE602004017777D1 (de)	2008-12-24	Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit
IL140070A0 (en)	2002-02-10	Benzamide derivatives and pharmaceutical compositions containing the same
ATE218860T1 (de)	2002-06-15	Verwendung von 3,4-diphenylchromanen zur herstellung eines arzneimittels zur behandlung bzw. vorbeugung des prostatakarzinoms
AU2904300A (en)	2000-08-01	Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
YU1302A (sh)	2005-03-15	Derivati aminotiazola i njihova primena kao liganada crf receptora
DK1147088T3 (da)	2006-05-15	6-arylphenanthridiner med PDE-IV-inhiberende aktivitet
GB9621814D0 (en)	1996-12-11	Metalloproteinase inhibitors
ATE223379T1 (de)	2002-09-15	N-aryloxyethylaminderivate zur behandlung der depression
DE69333270D1 (de)	2003-12-04	Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
AU758194C (en)	2004-04-08	Novel benzimidazoles and benzoxazoles
TR199902097A2 (xx)	2000-03-21	Mikrobial transformasyon.